Supplementary Figure 1 from SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Open Access
- 31 March 2023
- other
- Published by American Association for Cancer Research (AACR)